Targeted therapy of colorectal cancer - state of the art

被引：0

作者：

Utracka-Hutka, Beata ^{[1
]}

机构：

[1] Ctr Onkol Marii Curie Sklodowskiej Oddzial Gliwic, Klin Onkol Klin, Ul Armii Krajowej 15, PL-44101 Gliwice, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2006年 / 10卷 / 03期

关键词：

words: Colorectal cancer; targeted therapy; epidermal growth factor receptor (EGFR); vascular endothelial growth factor (VEGF);

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The recent development of drugs that target the key components of biologic pathways rendered an improvement in survival in colorectal cancer patients. Two monoclonal antibodies in particular, targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) - bevacizumab and cetuximab are clinically available. The expectations with low molecular weight tyrosine kinase inhibitors in the treatment of colorectal cancer have not been confirmed. This review focuses on the defining role of the novel targeted agents in colorectal cancer.

引用

页码：121 / 127

页数：7

共 35 条

[1]

American Cancer Society, 2005, CANC FACTS FIG

[2] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

[3]

CHO CD, 2003, P AN M AM SOC CLIN, V22, P265

[4] Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence [J].

Choi, HJ ;

Hyun, MS ;

Jung, GJ ;

Kim, SS ;

Hong, SH .

ONCOLOGY, 1998, 55 (06) :575-581

[5] Antibody-based therapies for colorectal cancer [J].

Chung, KY ;

Saltz, LB .

ONCOLOGIST, 2005, 10 (09) :701-709

[6] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[7] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[8]

DIDKOWSKA J, 2003, NOWOTWORY ZLOSLIWE P

[9]

DORLIGSCHAW O, 2003, P AN M AM SOC CLIN, V22, P372

[10]

GIANTONIO BJ, 2005, AM SOC CLIN ONC GAST

← 1 2 3 4 →